Growth Hormone-Releasing Hormone clinical trials
How each study uses Growth Hormone-Releasing Hormone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
Massachusetts General Hospital (2) · The University of Texas Medical Branch, Galveston (1) · Columbia University (1) · University of Pennsylvania (1) · Johns Hopkins University (1) · Cairo University (1)
Often tested with
Tested in the same studies.
Growth Hormone (1) · Arginine (1) · Dehydroepiandrosterone (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Growth Hormone-Releasing Hormone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Adult Growth Hormone Deficiency and Cardiovascular RiskTerminatedPhase 4Columbia UniversityNCT00720902Written as growth hormone releasing hormone (GHRH) & arginine
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentCompletedPhase 1The University of Texas Medical Branch, GalvestonNCT02553603Written as Growth Hormone Releasing Hormone (GHRH)
- Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyTerminatedPhase 2University of PennsylvaniaNCT01410799Written as Growth Hormone Releasing Hormone (GHRH )
- Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyTerminatedPhase 2Johns Hopkins UniversityNCT00807365Written as GHRH
- Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian ResponseStatus unknownPhase 3Cairo UniversityNCT02736591Written as Growth Hormone-Releasing Hormone
- Effects of Short-term Growth Hormone in HIV-infected PatientsCompletedNot applicableMassachusetts General HospitalNCT00795210Written as Growth Hormone Releasing Hormone
- Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenCompletedNot applicableMassachusetts General HospitalNCT00850564Written as Growth Hormone Releasing Hormone (Tesamorelin)
Codes
What other systems call Growth Hormone-Releasing Hormone · ClinicalTrials.gg INT008224
- MeSH (NLM) D013007Growth Hormone-Releasing HormoneOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D013007 | Growth Hormone-Releasing Hormone | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.